biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech's Glioblastoma Drug and xB3 Synergy:

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 15, 2023 6:08pm

66 Views

Post# 35224506

RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

"It's also essential to recognize one of the main receptors Transcend utilizes to trick the brain into opening the BBB is expressed in important regions of the brain, including areas critical to learning, memory, mood and impulsivity. This receptor is significantly expressed in glioblastomas and in key areas of the brain involved in a plethora of psychiatric and neurological diseases. I think these represent very intriguing targets for biOasis."

You don't have to be an all-or-none thinker. Perhaps it is the case that Midatech's brain delivery technology can better deliver a drug to a certain region of the brain than IV administration and further avoid toxicity. IV administration delivers a drug systemically throughout the whole body needlessly exposing the whole body to more of the drug. What about using Midatech's delivery technology in the case of glioblastoma to deliver xB3 drug directly to the glioblastoma tumor site? xB3 drug further targets glioblastoma at th site of the tumor. Targeted delivery with targeted receptor and limited exposure of the rest of the body to the drug.

Boomskid wrote: Ohhhhhhhhhhhhh, I didn't realize that Midatech had a better brain delivery technology than xB3. I thought i read that Stephen Stamp was happy to get xB3.

Well, I guess Bioasis was wrong in that 2017 quote.

So, why, exactly, did you copy/paste it?

jd